US20180147147A1 - Oral delivery system for bioactive agents - Google Patents
Oral delivery system for bioactive agents Download PDFInfo
- Publication number
- US20180147147A1 US20180147147A1 US15/579,466 US201615579466A US2018147147A1 US 20180147147 A1 US20180147147 A1 US 20180147147A1 US 201615579466 A US201615579466 A US 201615579466A US 2018147147 A1 US2018147147 A1 US 2018147147A1
- Authority
- US
- United States
- Prior art keywords
- alginate
- fish
- ethylenediammonium
- oral delivery
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012867 bioactive agent Substances 0.000 title claims description 36
- 229920000615 alginic acid Polymers 0.000 claims abstract description 136
- 229940072056 alginate Drugs 0.000 claims abstract description 124
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 118
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 107
- 241000251468 Actinopterygii Species 0.000 claims abstract description 70
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000011324 bead Substances 0.000 claims description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 13
- 230000002496 gastric effect Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 241000277331 Salmonidae Species 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 241000276457 Gadidae Species 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- -1 immune stimulants Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 241001519451 Abramis brama Species 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241000277320 Pangasius Species 0.000 claims description 3
- 241000269980 Pleuronectidae Species 0.000 claims description 3
- 241000269978 Pleuronectiformes Species 0.000 claims description 3
- 241000157468 Reinhardtius hippoglossoides Species 0.000 claims description 3
- 241001417495 Serranidae Species 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 241000276707 Tilapia Species 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 abstract description 8
- 229920002521 macromolecule Polymers 0.000 abstract description 3
- 235000019688 fish Nutrition 0.000 description 62
- 239000000243 solution Substances 0.000 description 41
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 39
- 238000012360 testing method Methods 0.000 description 32
- 238000000034 method Methods 0.000 description 31
- 210000000936 intestine Anatomy 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 238000004090 dissolution Methods 0.000 description 22
- 239000000872 buffer Substances 0.000 description 19
- 239000008188 pellet Substances 0.000 description 18
- 238000007922 dissolution test Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004132 cross linking Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 229920002307 Dextran Polymers 0.000 description 14
- 239000012738 dissolution medium Substances 0.000 description 14
- 238000005538 encapsulation Methods 0.000 description 12
- 239000011325 microbead Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 230000002378 acidificating effect Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000277263 Salmo Species 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000000783 alginic acid Substances 0.000 description 6
- 229960001126 alginic acid Drugs 0.000 description 6
- 150000004781 alginic acids Chemical class 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000001079 digestive effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000661 sodium alginate Substances 0.000 description 6
- 235000010413 sodium alginate Nutrition 0.000 description 6
- 229940005550 sodium alginate Drugs 0.000 description 6
- 239000008279 sol Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000648 calcium alginate Substances 0.000 description 4
- 235000010410 calcium alginate Nutrition 0.000 description 4
- 229960002681 calcium alginate Drugs 0.000 description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000277275 Oncorhynchus mykiss Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 241000277289 Salmo salar Species 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 3
- 238000003366 endpoint assay Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000009755 vacuum infusion Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007641 inkjet printing Methods 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 241001507086 salmonid fish Species 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000304829 Durvillaea Species 0.000 description 1
- 241001512723 Ecklonia Species 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- 241000681116 Laminaria sp. Species 0.000 description 1
- 241001512709 Lessonia <stramenopiles> Species 0.000 description 1
- 241001491705 Macrocystis pyrifera Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 229910019145 PO4.2H2O Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- 241001260858 Sargassum sp. Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003653 coastal water Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- HCFPRFJJTHMING-UHFFFAOYSA-N ethane-1,2-diamine;hydron;chloride Chemical compound [Cl-].NCC[NH3+] HCFPRFJJTHMING-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020912 omnivore Nutrition 0.000 description 1
- 244000054334 omnivore Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Definitions
- the present invention relates to an oral delivery system, to ethylenediammonium alginate for use as an oral delivery system, and to a functional feed as defined in the introductory parts of the independent claims. Furthermore, the present invention relates to a method of producing ethylenediammonium alginate particles and to methods of producing a functional feed in pellet form comprising at least one bioactive agent.
- bioactive agents are crucial for their later uptake and efficacy in the organism.
- the way of how such bioactive agents are administered is therefor of great importance.
- Oral drug delivery is the method of swallowing a pharmaceutical compound with the intention of releasing it into the gastrointestinal tract of humans and animals.
- one challenge is the potential deactivation or break down of active agents in the stomach before they can be absorbed in the gut.
- Many of the bioactive agents are thermo sensitive and prone to acidic and proteolytic degradation in the gastro intestinal tract. This is in particular the case for proteins.
- Another problem is the delivery to the right target organ for uptake as well as an efficient absorbance.
- Atlantic salmon Salmo salar
- the digestive tract of salmon being a carnivorous fish can be subdivided into a foregut (mouth, oesophagus and stomach), a midgut (pyloric ceca or proximal intestine and mid intestine) and a hindgut or a distal intestine terminating in the rectum.
- Digestion is a catabolic process of solubilising and degrading nutrients into smaller components that are more easily absorbed into a blood stream.
- the major digestive components secreted in the stomach are pepsinogen and hydrochloric acid (HCl) and secretion of both of them are stimulated by feed intake. It was shown that an average gastric pH of 2.7 increases to 4.9 when the salmonid rainbow trout ( Oncorhynchus mykiss ) goes from starved to fed state (Bucking, C. and Wood, C. M. 2009. The effect of postprandial changes in pH along the gastrointestinal tract on the distribution of ions between the solid and fluid phases of the chyme in rainbow trout. Aquaculture Nutrition, Vol. 15, Issue 3, pp 282-296). The increased pH is maintained for eight hours post-feeding.
- the pyloric caeca constitute a compartment where other proteolytic enzymes like trypsin, chymotrypsin and aminopeptidase are completing the peptide hydrolysis. It is well known that most proteins are absorbed into the blood stream as free amino acids and short peptides in the pyloric region. When the acidic chyme reaches the proximal intestine, it becomes rapidly neutralised by bicarbonate (HCO 3 ⁇ ) in bile and pancreatic juice.
- HCO 3 ⁇ bicarbonate
- Bucking and Wood (2009) observed an average pH of 8.2 throughout the whole intestinal section in fasted fish. After feeding, the pH decreased to 7.5 in the proximal and mid intestine, while it remained almost unchanged in the distal section. However, the pH increased again in the period after feeding in the intestine, reaching its highest value after eight hours. At that point, the pH can be above 8.5 all along the intestinal tract with increasing trend towards the distal part.
- Another challenge for delivery of agents is that the passage time of feed material through the entire digestive system of carnivorous fish can be very short.
- the transit time depends on meal size, feed composition and structure, and it could be anything from 5 to 35 hours after feed intake.
- the right choice of a suitable delivery agent is therefore of great importance.
- An important characteristic for the suitability of an oral delivery system is the proper dissolution of the delivery agent in order to release the bioactive composition at the right time and place in the intestinal system.
- Cross-linked alginates are polymers which have typically been used in oral delivery systems.
- the cross-linking properties of alginate form the basis for various encapsulation techniques including both extrusion and emulsion processes.
- Alginates can be cross-linked using a variety of known cross-linking agents. The most commonly used cross-linking agent is Ca 2+ .
- Alginates are polysaccharides isolated from brown algae such as Ascophyllum nodosum, Durvillaea sp., Ecklonia sp., Laminaria sp., Lessonia sp., Sargassum sp. and Macrocystis pyrifera found in coastal waters around the globe. Marine alginates are composed of two forms of uronic acid: mannuronic (M) and guluronic (G). Two blocks of adjacent polymer chains can be cross-linked with multivalent cations (e.g.
- cross-linked alginate has an excellent biocompatibility within host tissues and is able to biodegrade in a controlled manner.
- Bioactive agents for oral delivery are typically encapsulated or entrapped in alginate during the process of cross-linking, particularly by encapsulation into small alginate beads.
- Cross-linked alginate beads are typically stable at low pH and dissolve at higher pH. As a result, a faster release from alginate beads occurs in the intestine (alkaline conditions), after the beads have passed through the proteolytic and acidic environment of the stomach.
- alginate matrices are not suitable or efficient for delivering bioactive agents to the lower gastrointestinal tract of animals with short intestine.
- the major shortcoming of commonly known oral delivery systems including alginate is incomplete or insufficient dissolution in the length-limited intestinal systems. This is especially the case in the gastric, carnivorous and omnivorous fish with preference to animal material which typically have a short intestinal tract such as salmonids, basses, breams, codfish, halibut, turbot, flounders, pangasius and grouper. Due to their short intestine, the retention time of feed material as well as the time window for release and uptake of active ingredients is rather limited.
- the objective technical problem of the present invention is to provide a vehicle for oral delivery of biologically active agents, particularly macromolecular drugs and therapeutic proteins to the intestine of animals.
- the present invention has the objective to provide a fast-dissolving and temperature-independent oral delivery system, in particular for species living in cold water.
- the present invention has the objective to provide an oral delivery system for use in fish, particularly in fish with a stomach and short intestinal tract.
- the present invention has the objective to provide an oral delivery system for use in gastric, carnivorous and omnivorous fish, and in particular for cold water fish such as salmonids.
- Another objective of the present invention aims to provide an oral delivery system that protects bioactive agents from acidic and proteolytic degradation in the stomach and then releases them in the intestinal region at an alkaline pH.
- the present invention relates to an oral delivery system comprising ethylenediammonium alginate and at least one bioactive agent for use in a therapeutic and/or prophylactic treatment.
- This oral delivery system owing to its favourable dissolution properties is particularly suitable for use in animals, especially in animals with a short intestinal tract such as carnivorous and omnivores fish with preference to animal material.
- the oral delivery system is very well suitable for oral delivery of bioactive substances to ectothermic animals which can have a digestion at low temperatures.
- said bioactive agent is encapsulated or entrapped in ethylenediammonium alginate.
- bioactive agent to be delivered is selected from the group consisting of proteins, peptides, vaccines, antibodies, antigens, hormones, enzymes, immune stimulants, drugs, probiotics, prebiotics, polynucleotides, nucleotides, and amino acids.
- the oral delivery system is for use in an ectothermic animal with a gastrointestinal tract comprising an intestine and a stomach, preferably in a cold water species, more preferably in fish.
- the present invention relates to an oral delivery system for use in a fish species selected from the group consisting of omnivorous and carnivorous species, preferably from a cold-water fish species.
- the oral delivery system is suitable for use in fish, preferably in a gastric fish, more preferably for a fish with a short intestinal tract, most preferably in a species selected from a group consisting of salmonids, basses, breams, codfish, halibut, turbot, flounders, grouper, tuna, tilapia, and pangasius.
- the present invention relates to ethylenediammonium alginate for use as an oral delivery system in a therapeutic and/or prophylactic treatment.
- a preferred use is in fish, more preferably in an omnivorous or carnivorous species. Even more preferred is a use in a cold-water fish.
- the alginate matrix is in a form of particles, preferably as beads, and most preferably in form of spherical beads.
- the ethylenediammonium alginate beads have a mean particle size in the range of 1 ⁇ m to 10 mm, more preferably in the range of 300 ⁇ m to 2000 ⁇ m.
- the mean particle size is no more than 300 ⁇ m, preferably is no more than 200 ⁇ m, more preferably is no more than 100 ⁇ m and most preferably is no more than 25 ⁇ m. This is an advantage when associating with feed pellet in a vacuum coater.
- the preferred mean size for pre-extrusional addition is less than 300 ⁇ m, the sizes between 300 ⁇ m and 2000 ⁇ m are feasible as well.
- the preferred mean size of alginate bead for standalone oral administration is greater than 100 ⁇ m and will depend on the size of both organism and target dose.
- the present invention relates to a functional feed comprising at least one bioactive agent encapsulated or entrapped in ethylenediammonium alginate.
- a functional feed comprising at least one bioactive agent encapsulated or entrapped in ethylenediammonium alginate.
- the incorporation of the alginate-encapsulated bioactive agent into feed pellets is an essential operation when it comes to animal feed, especially fish feed. Effective incorporation into a feed pellet reduces the loss of bioactive ingredients due to handling of feed and ensures a constant supply of prescribed doses.
- the alginate comprising the bioactive agent in the functional feed is in form of beads.
- the ethylenediammonium alginate is shaped as particles, preferably as beads and most preferably in form of spherical beads.
- the mean particle size of the alginate beads is no more than 2000 ⁇ m, preferably no more than 1000 ⁇ m, more preferably no more than 300 ⁇ m, and most preferably no more than 25 ⁇ m.
- the present invention relates to a functional feed comprising at least one bioactive agent encapsulated in ethylenediammonium alginate for use in therapeutic and/or prophylactic treatment.
- a preferred use of the functional feed is in fish.
- the present invention relates to a method of producing ethylenediammonium alginate particles comprising at least one bioactive agent by a process of cross-linking alginate with ethylenediammonium whereby the desired alginate shape is formed by means of (i) an extrusion method prior to curing in an ethylenediammonium solution or (ii) an emulsion method.
- the desired alginate shape and size are either formed by means of the extrusion method prior to curing in an ethylenediammonium solution or by the emulsion method in combination with said ethylenediammonium.
- the extrusion method (i) can be selected from a group consisting of aerodynamically assisted jetting, electromagnetic laminar jet breakup, inkjet printing, 3D printing, electro spraying, and coaxial air flow induced dripping and wherein the emulsion method (ii) can be a method selected from the group consisting of coacervation, internal gelation, and external gelation.
- the method can comprise the following steps:
- the present invention relates to a method of producing a functional feed comprising at least one bioactive agent wherein the method comprises the following steps:
- the present invention relates to a method of producing functional feed containing at least one bioactive agent wherein the method comprises the following steps:
- FIG. 2 shows dissolution profiles as curves of the mean percentage of cumulative blue dextran (BD) release from alginate beads over time. Dissolution tests performed in potassium hydrogen phthalate/HCl buffer (pH 3.0) for 15 min followed by phosphate buffer (pH 8.0) for the next 50 min. Release was below LoQ (3.9 ⁇ 10 ⁇ 3 mg ml ⁇ 1 ) in the acidic medium so the figure depicts only release in the alkaline dissolution medium. The error bars represent standard deviation (SD) based on five samples at each point.
- BD-EDA-alg denotes ethylenediammonium alginate beads loaded with BD; BD-Ca-alg means calcium alginate beads loaded with BD;
- FIG. 3 shows the HRP concentration in four gastrointestinal compartments (stomach, pyloric caeca, mid and distal intestine) of three groups of A. salmon (Ca-alginate, EDA-alginate and Control). The error bars represent 95% confidence intervals.
- the Ca-alginate group received calcium alginate encapsulated HRP (HRP-Ca-alg).
- EDA-alginate group received ethylenediammonium alginate encapsulated HRP (HRP-EDA-alg).
- the Control group did not receive any HRP.
- the present invention provides a novel oral delivery system for delivery of bioactive agents to the intestine.
- This oral delivery system is particularly suitable for use in organisms with a short intestinal tract such as carnivorous fish.
- the oral delivery system is suitable for oral delivery of bioactive substances in ectothermic animals which can have a digestion at low temperatures.
- sodium alginate is cross-linked with ethylenediamine dihydrochloride to form ethylenediammonium alginate.
- ethylenediamine dihydrochloride to form ethylenediammonium alginate.
- ethylenediammonium alginate is used as an oral delivery system for bioactive agents, in particular in fish.
- the agents are encapsulated or entrapped in the matrix of ethylenediammonium alginate during the process of cross-linking alginate with ethylenediammonium dications.
- small alginate microbeads are produced during this cross-linking process consisting of two major steps: 1) generating of alginate droplets by devices such as spray or jetting heads fitted with nozzles as those found in aerodynamically assisted jetting or by other methods known to the skilled person for generating droplets of liquids (e.g.
- aerodynamically assisted jetting electromagnetic laminar jet breakup, inkjet printing, 3D printing, electro spraying, coaxial air flow induced dripping etc.
- 2) collecting alginate droplets in cross-linking solution containing ethylenediammonium emulsion method (e.g. coacervation, internal and external gelation etc.) can be used in combination with ethylenediammonium.
- the ethylenediammonium alginate matrix can typically have the form of any geometric particle shape for particles e.g. fibre, sphere, toroid, ellipsoid and also including fibres and flakes.
- the particles are regular shaped, although said alginate matrix can also be in form of an irregularly shaped particle.
- said matrix is in form of beads, more preferred in form of spherical beads.
- the resulting alginate beads comprising bioactive agent(s) can be enterally administered either in feed or ex feed (independently, without regard to feed) to target organisms.
- the preferred mean particle size of the alginate beads is in the range of 1 ⁇ m to 10 mm.
- the mean size of alginate beads can typically be in the range of 300 ⁇ m and 2000 ⁇ m.
- the preferred mean size for pre-extrusional addition is less than 300 ⁇ m.
- Preferred particles sizes are less than 300 ⁇ m, more preferable less than 100 ⁇ m and most preferable less than 25 ⁇ m.
- the preferred mean size of alginate beads for stand-alone administration (without being in cooperated in a feed) is greater than 100 ⁇ m.
- the preferred size of the beads will typically depend on both, the size of the animal and target dose and may be adjusted correspondingly.
- the preferred route of administration to fish is the oral route with alginate beads in feed.
- the small alginate beads comprising bioactive agent(s) are preferably incorporated into feed pellets by a suitable method such as vacuum infusion coating, before they are orally administered to target organisms, such as a fish.
- the beads can be mixed with other feed ingredients before pelletizing. These ingredients can for example be conventional feed components known to a skilled person.
- the alginate beads comprising one or several bioactive ingredient(s) are mixed with initial flour (dry mix consisting of all feed ingredients except from oil) prior to extrusion or any other means of making feed pellets.
- EDA-alginate ethylenediammonium alginate
- the oral delivery system according to the present invention was tested both, in a known standard dissolution test as well as in a test, which has been adapted to the digestive conditions that are representative for ectothermic salmonid fish. Firstly, release of blue dextran from Ca-alginate and EDA-alginate was assessed in vitro in a standard dissolution test (pH 1.2 and pH 6.8 at 37° C.). Secondly, release from the same alginates was tested in alkaline dissolution media of pH 8.0 and pH 8.6 at 18° C.
- HRP horseradish peroxidase
- Sodium alginate (Protanal LF 20/40) was obtained from FMC BioPolymer AS (Norway). Horseradish Peroxidase (HRP, P/N 31491, Thermo Fisher Scientific) was acquired from Perbio Science UK Ltd. Deionised water (DI water, analytical reagent) was purchased from Fishe Chemical Ltd. (UK).
- the following reagents were purchased from VWR Ltd (UK): calcium chloride dihydrate (AnalaR NORMAPUR®, ACS analytical reagent), sodium bicarbonate (AnalaR NORMAPUR®, ACS analytical reagent), sodium hydroxide (98%, flake, Alfa Aesar), potassium hydrogen phthalate (99%, Alfa Aesar) and hydrochloric acid (37%, AnalaR NORMAPUR®, analytical reagent).
- the following reagents were purchased from Sigma-Aldrich Ltd. (UK):
- EWOS Opal 200 base pellet (BP, 5.8% fat) was produced at Technology Centre of EWOS Innovation AS in Dirdal (Norway). Fish oil (EWOS ID: 20180) was acquired from Egersund Sildoljefabrikk AS (Egersund, Norway).
- Blue dextran encapsulation formulation (BD-EncForm) was prepared by dissolving sodium alginate (2.0% w/v) in a BD solution (50.0 mg ml ⁇ 1 ) at ambient temperature.
- Buffer pH 1.2 Sodium chloride/hydrochloric acid (NaCl/HCl, pH 1.2) buffer was prepared by mixing NaCl solution (250 ml, 23.38 g 1 ⁇ 1 , 0.4M NaCl) with 0.4M HCl solution (425 ml). Before making up the volume to 1000 ml with DI water, the pH of the buffer solution was adjusted to 1.2.
- Buffer pH 3.0 Potassium hydrogen phthalate solution (500 ml, 81.69 g 1 ⁇ 1 , 0.4M KPH) was combined with HCl solution (223 ml, 0.4M HCl) to produce stock solution of KPH/HCl buffer (pH 3.0). The buffer solution was replenished with DI water to a total volume of 1000 ml.
- Buffer pH 6.8 Monosodium phosphate dihydrate solution (255 ml, 62.40 g 1 ⁇ 1 , 0.4M NaH 2 PO 4 .2H 2 O) was mixed with disodium phosphate dihydrate solution (245 ml, 71.20 g 1 ⁇ 1 , 0.4M Na 2 HPO 4 .2H 2 O) to form phosphate buffer (pH 6.8). The resulting buffer was adjusted to pH 6.8 before levelling the volume to 1000 ml with DI water.
- Buffer pH 8.0 Phosphate buffer (pH 8.0) was made by combining monosodium phosphate dihydrate solution (26.5 ml, 62.40 g 1 ⁇ 1 , 0.4M NaH 2 PO 4 .H 2 O) with disodium phosphate dihydrate solution (473.5 ml, 71.20 g 1 ⁇ 1 , 0.4M Na 2 HPO 4 .2H 2 O). The resulting buffer solution was adjusted to pH 8.0 and then diluted with DI water to a final volume of 1000 ml.
- Buffer pH 8.6 Glycine solution (250 ml, 30.03 g 1 ⁇ 1 , 0.4M Gly) was mixed with sodium hydroxide solution (20 ml, 16 g 1 ⁇ 1 , 0.4M NaOH) to produce Gly/NaOH buffer. After adjusting the pH to 8.6, the generated buffer solution was diluted to a volume of 1000 ml with DI water.
- HRP-EncForm Horseradish Peroxidase (HRP) encapsulation formulation
- HRP stock solution (5 mg ml ⁇ 1 ) was prepared by dissolving HRP powder (10.0 mg) in DI water (2.0 ml). Aliquots of this HRP solution (20.0 ⁇ l) were stored at ⁇ 20° C. prior to constructing the standard curves in the enzyme assay.
- the cross-linking solutions (CaCl 2 sol. and EDA.2HCl sol.) were prepared by separately dissolving calcium chloride dihydrate (36.8 g 1 ⁇ 1 , 0.25M CaCl 2 .2H 2 O) and ethylenediamine dihydrochloride (33.3 g 1 ⁇ 1 , 0.25M EDA.2HCl) in DI water.
- Blue dextran was selected as a model compound for the simulated release of active pharmaceutical ingredients (API) from alginate matrices.
- This set up was used to extrude 80 batches of BD-EncForm à 1.50 ml each.
- BD-Ca-alg 40 batches
- BD-EDA-alg beads 40 batches respectively.
- alginate beads were separated from the cross-linking solution 10 min after the last bead was generated. Thereafter, the recovered alginate beads loaded with BD were washed with DI water (3 ⁇ 5 ml).
- BD-Ca-alg (10 batches) and BD-EDA-alg beads (10 batches) were used to determine encapsulation efficiency while the remaining batches were utilised in dissolution tests.
- the particle size distribution and shape were determined by a stereo microscope (Leica MZ10 F, Leica Microsystems, Wetzlar, Germany).
- BD concentration of the samples was determined by using standard curve in the range of 1.0 to 3.9 ⁇ 10 ⁇ 3 mg ml ⁇ 1 . Standard curves were generated by plotting BD concentrations of nine two-fold serial dilutions of BD solution (1.0 mg ml ⁇ 1 ) versus absorbance.
- Dissolution medium 300 ml; NaCl/HCl buffer, pH 1.2 or phosphate buffer, pH 6.8, was added into each of the vessels and then allowed to temperate overnight at 37° C.
- the dissolution experiment started within 2 h after producing alginate beads according to the method described above.
- the alginate beads (BD-Ca-alg or BD-EDA-alg) were placed into rotating baskets (100 rpm) and then submerged into dissolution vessels.
- Samples (1.0 ml sample ⁇ 1 ) were taken from the vessel at five minutes intervals through an extent of 50 minutes. An equivalent volume of dissolution medium (1.0 ml, 37° C.) was then added to keep the liquid level in the vessels constant. All samples were filtered through a syringe filter (0.45 ⁇ m, VWR) before placing them onto a 96-well polystyrene plate (NuncTM, Sigma-Aldrich) for an endpoint assay. Reading of the plate was performed by a VERSAmax microplate reader (Molecular Devices LLC, Sunnyvale, Calif., USA) at 610 nm and 24° C. Amount of BD released was determined by applying standard curve approach.
- Standard curves were generated by plotting BD concentrations of nine two-fold serial dilutions of BD solution (1.0 mg ml ⁇ 1 ) versus absorbance in the range of 1.0 to 3.9 ⁇ 10 ⁇ 3 mg ml ⁇ 1 .
- alginate beads were first submerged into acidic dissolution medium (KPH/HCl buffer, pH 3.0) for 15 min and then the acidic buffer solution was replaced with an alkaline dissolution medium (phosphate buffer, pH 8.0).
- acidic dissolution medium KPH/HCl buffer, pH 3.0
- alkaline dissolution medium phosphate buffer, pH 8.0
- the same UPS Apparatus 1 was used.
- two different temperatures (4° C. and 18° C.) were applied in the test. The chosen temperatures typically correspond to the water temperatures during summer and winter at the Norwegian coast.
- Mean size of the Ca-alginate beads was 3.0 mm while the mean size of the EDA-alginate beads was 3.7 mm.
- the shape of the beads was spherical for both types of beads ( FIG. 1 ).
- Drugs which are encapsulated in alginate matrices, are principally released by two mechanisms: 1) diffusion of the drug through the pores of the polymer network and 2) degradation of the polymer network.
- M.W. 2,000,000
- a very low release rate of fluorescein isothiocyanate dextran was observed at pH 7.4 during the first hour.
- EDA-alginate Very little degradation of EDA-alginate is expected to occur at pH 3.5-7.0 since most of the ethylenediamine (uncharged form) will exist as ethylenediammonium (positively charged) at a pH ⁇ 7.0 and most of the alginate (alginic acid) will be deprotonated (negatively charged) at pH>3.5.
- an effective way to weaken the cross-linked structure of an alginate matrix is to use an acidic dissolution medium (pH ⁇ 3.5) before applying an alkaline medium (pH>7.0).
- an acidic dissolution medium pH ⁇ 3.5
- an alkaline medium pH>7.0
- hydrogen ions H +
- alginic acid is poorly water soluble, it is easily convertible to an aqueous soluble form (e.g. sodium alginate) at higher pH.
- an increasing alkaline pH (pH>7.0) is reducing the crosslinking strength of ethylenediammonium through deprotonation of its amine groups and conversion to ethylenediamine, the uncharged form.
- EDA-alginate has a high efficiency and potential as oral delivery system under conditions typically found in fish, where the gastric pH is 2.7-4.9 and the intestinal pH is 7.5-8.5.
- HRP-Ca-alg Calcium alginate
- HRP-EDA-alg ethylenediammonium alginate
- microbeads loaded with HRP were produced in an encapsulation process referred as aerodynamically assisted jetting.
- jet of alginate droplets was generated by extruding HRP-EncForm (2 ⁇ 240.0 g) through a jetting head by means of air pressure.
- the created jet was directed towards the surface of a cross-linking solution from a distance of 100 mm.
- the cross-linking solutions CaCl 2 sol.
- the resulting microbeads were filtered off by suction filtration and washed with DI water (3 ⁇ 20 ml) before storing at ⁇ 20° C.
- the obtained mass of HRP-Ca-alg and HRP-EDA-alg microbeads was 81.54 g and 78.29 g, respectively.
- Laser diffraction system HELOS BR CUVETTE, CUV-50ML/US, optical module R5, Sympatec GmbH, Clausthal-Zellerfeld, Germany
- was used to measure the size of generated alginate beads at wavelength A 632.8 nm.
- the median diameter of the microbeads was 25-26 ⁇ m.
- the obtained beads shall be incorporated into a feed pellet via the surface, than the diameter of the microbeads must correspond to the pore size of the pellet. This is achieved by the above described method.
- HRP-Ca-feed was prepared by coating BP (3708.46 g) with oil suspension containing HRP-Ca-alg (81.54 g) while HRP-EDA-feed was made ready by applying oil suspension containing HRP-EDA-alg (78.29 g) to BP (3711.71 g) in a vacuum coater.
- Control feed (Ctrl-feed) without HRP was produced by coating BP (3790.00 g) with fish oil (1210.00 g) only.
- the tanks were randomly divided into three groups (Ca-alginate, EDA-alginate and Control), with three tanks being assigned to each group.
- the Ca-alginate and EDA-alginate group of fish were treated with HRP-Ca-feed and HRP-EDA-feed, respectively.
- the Control group was fed Ctrl-feed.
- the treatment lasted for two weeks after which followed a sampling. The health status of the fish was very good during the 11 weeks long span of the trial.
- TMB 3,3′,5,5′-tetramethylbenzidine
- HRP concentration of the samples was determined by using standard curve as a quantification tool in the range of 0.391 to 200 ng ml ⁇ 1 .
- a standard curve was generated by plotting HRP concentrations of 10 two-fold serial dilutions of HRP solution (200 ng ml ⁇ 1 ) against their kinetic rates (slope of the absorbance versus time curves).
- HRP dose related to the fish size in unit of mass and the weekly feed intake (FI) per fish.
- the dose is shown as a weekly HRP dose per fish ( ⁇ g fish ⁇ 1 week ⁇ 1 ) and a weekly HRP dose per unit of fish mass ( ⁇ g fish ⁇ 1 week ⁇ 1 ).
- the group of fish (Ca-alginate) fed HRP-Ca-feed showed significantly higher concentration of HRP in the distal intestine compared to the other gastrointestinal (GI) compartments ( FIG. 3 ).
- fish fed HRP-EDA-feed had significantly higher concentration of HRP in the mid intestine than in the other GI sections. Additionally, this group had also notably higher HRP concentration in the distal intestine. In contrast to the HRP treated groups, peroxidase activity was quite low in the control group.
- EDA-alginate is an excellent delivery system for macromolecular drugs to ectothermic animals like salmon. Furthermore, there is convincing evidence that this delivery system is surprisingly temperature-independent within the temperature range of salmon's life habitat. The practical implication of the results of the present study is that the amount of drug delivered is irrespective of the environmental temperature when using this novel oral delivery system.
- ethylenediammonium alginate micro beads as oral delivery system when incorporated in fish feed and orally administered to fish, is that the beads efficiently dissolve in the fish intestine and deliver the content at the right place for absorbance in the digestive conditions as typically found in fish.
- the present invention even though being found particularly suitable for use in fish, is not restricted to this group of organisms and may likewise also be used as oral delivery systems for macromolecules in mammals including humans, amphibians, reptiles, birds, crustaceans, molluscs, etc.
- Bioactive agent in accordance with the present invention includes any drug, substance, compound, composition or mixture thereof, which are effective in therapy or prophylactic treatment in organisms and which are suitable for encapsulation in alginate and following oral delivery.
- This includes agents such as proteins, peptides, vaccines, antibodies, antigens, hormones, drugs, particularly macromolecular drugs, amino acids, nucleotides, polynucleotides, enzymes, any physiologically active substance, nutrients, prebiotics, probiotics, immune stimulants and the like.
- a “cold water fish” is a fish living in average water temperatures of about 20° C. or lower.
- Typical examples for cold water fish are cold water marine fish such as codfish and salmonids.
- short intestinal tract or “short intestine” in relation to a fish is meant that the total length of the intestine is no more than about 2.5 times the body length of said fish.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1509608.4 | 2015-06-03 | ||
NO20150715 | 2015-06-03 | ||
GB1509608.4A GB2539006A (en) | 2015-06-03 | 2015-06-03 | Functional feed |
NO20150715A NO344096B1 (en) | 2015-06-03 | 2015-06-03 | Oral delivery system for bioactive active agents |
PCT/NO2016/050113 WO2016195509A1 (en) | 2015-06-03 | 2016-06-02 | Oral delivery system for bioactive agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO2016/050113 A-371-Of-International WO2016195509A1 (en) | 2015-06-03 | 2016-06-02 | Oral delivery system for bioactive agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/929,556 Continuation US11844863B2 (en) | 2015-06-03 | 2022-09-02 | Oral delivery system for bioactive agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180147147A1 true US20180147147A1 (en) | 2018-05-31 |
Family
ID=56360457
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/579,466 Abandoned US20180147147A1 (en) | 2015-06-03 | 2016-06-02 | Oral delivery system for bioactive agents |
US17/929,556 Active US11844863B2 (en) | 2015-06-03 | 2022-09-02 | Oral delivery system for bioactive agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/929,556 Active US11844863B2 (en) | 2015-06-03 | 2022-09-02 | Oral delivery system for bioactive agents |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180147147A1 (es) |
EP (2) | EP3302445A1 (es) |
CN (1) | CN108076627B (es) |
BR (1) | BR112017026013B1 (es) |
CA (1) | CA2987932C (es) |
CL (1) | CL2017003077A1 (es) |
EC (1) | ECSP18000069A (es) |
MX (1) | MX2017015545A (es) |
WO (1) | WO2016195509A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018126394B4 (de) * | 2018-10-23 | 2020-12-24 | Universität Rostock | Probiotika enthaltendes Depotsystem für dentale Anwendungen |
KR20230171094A (ko) * | 2022-06-13 | 2023-12-20 | 부산대학교 산학협력단 | 산성 환경에서 프로바이오틱스를 보호하는 하이드록시아파타이트-하이드로겔 복합체 및 이를 포함하는 프로바이오틱스 전달용 조성물 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935250A (en) * | 1984-05-01 | 1990-06-19 | Inverness Management Corporation | Coated fish feed pellets |
GB2270920B (en) * | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
US5658592A (en) * | 1994-05-13 | 1997-08-19 | Kuraray Co., Ltd. | Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane |
SE9401738D0 (sv) * | 1994-05-19 | 1994-05-19 | Ewos Ab | Bioactive feed |
FR2799196B1 (fr) * | 1999-10-04 | 2002-02-08 | Sod Conseils Rech Applic | Copolymeres reticules a base de copolymeres polycarboxyliques non reticules |
JP4565691B2 (ja) * | 2000-02-28 | 2010-10-20 | 株式会社Phg | ヘパリン結合性成長因子用徐放基材、およびヘパリン結合性成長因子徐放剤 |
SE0103613D0 (sv) * | 2001-10-30 | 2001-10-30 | Astrazeneca Ab | Novel formulation |
NO320671B1 (no) * | 2001-11-30 | 2006-01-16 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning i fisk. |
WO2004043140A2 (en) * | 2002-11-07 | 2004-05-27 | Advanced Bionutrition Corp. | Nutraceuticals and method of feeding aquatic animals |
CN1268346C (zh) * | 2003-11-19 | 2006-08-09 | 上海中科伍佰豪生物工程有限公司 | 生物多糖微胶囊及其制备方法和用途 |
US20080044481A1 (en) * | 2004-05-27 | 2008-02-21 | Mordechai Harel | Microparticles for Oral Delivery |
ITMI20052461A1 (it) * | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
CN101549158A (zh) | 2009-05-08 | 2009-10-07 | 南开大学 | 一种海藻酸钠肝靶向纳米给药系统及其制备方法 |
US20130129865A1 (en) | 2010-08-03 | 2013-05-23 | Jorrocks Pty Ltd | Vacuum infusion for the inclusion of a supplement into food products |
UA103834C2 (ru) * | 2012-06-15 | 2013-11-25 | Павел Петрович Пивоваров | Капсулированный белоксодержащий продукт и способ его получения |
CN103627010A (zh) * | 2013-11-18 | 2014-03-12 | 戴建英 | 一种海藻酸酰胺类医用敷料的制备方法 |
-
2016
- 2016-06-02 MX MX2017015545A patent/MX2017015545A/es unknown
- 2016-06-02 EP EP16735733.4A patent/EP3302445A1/en not_active Ceased
- 2016-06-02 CA CA2987932A patent/CA2987932C/en active Active
- 2016-06-02 EP EP21156116.2A patent/EP3881835A1/en active Pending
- 2016-06-02 BR BR112017026013-1A patent/BR112017026013B1/pt active IP Right Grant
- 2016-06-02 CN CN201680032564.0A patent/CN108076627B/zh active Active
- 2016-06-02 US US15/579,466 patent/US20180147147A1/en not_active Abandoned
- 2016-06-02 WO PCT/NO2016/050113 patent/WO2016195509A1/en active Application Filing
-
2017
- 2017-12-01 CL CL2017003077A patent/CL2017003077A1/es unknown
-
2018
- 2018-01-02 EC ECIEPI201869A patent/ECSP18000069A/es unknown
-
2022
- 2022-09-02 US US17/929,556 patent/US11844863B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112017026013A2 (pt) | 2018-08-14 |
CA2987932A1 (en) | 2016-12-08 |
US20220409541A1 (en) | 2022-12-29 |
CA2987932C (en) | 2024-01-16 |
CN108076627A (zh) | 2018-05-25 |
WO2016195509A1 (en) | 2016-12-08 |
US11844863B2 (en) | 2023-12-19 |
EP3881835A1 (en) | 2021-09-22 |
MX2017015545A (es) | 2018-11-09 |
EP3302445A1 (en) | 2018-04-11 |
BR112017026013B1 (pt) | 2023-12-05 |
ECSP18000069A (es) | 2018-10-31 |
CN108076627B (zh) | 2021-05-25 |
CL2017003077A1 (es) | 2019-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11844863B2 (en) | Oral delivery system for bioactive agents | |
CN1243547C (zh) | 新的制剂 | |
JP4463109B2 (ja) | 栄養補助食品および水生動物の給餌方法 | |
CN1174745C (zh) | 膜衣用作口服剂型的味道掩蔽包衣的用途 | |
CN1107497C (zh) | 控制药物释放的制剂 | |
EP0260186B1 (fr) | Nouvelles compositions pour l'enrobage des additifs alimentaires destinés aux ruminants et additifs alimentaires ainsi enrobés | |
JP7018239B2 (ja) | ルーメンバイパス塩化コリンマイクロカプセル及びその製造方法 | |
CN102065843B (zh) | 口腔可分散的甘露醇 | |
CN1096869C (zh) | 动物生长激素的缓释组合物及其制备方法 | |
WO2004100941A1 (en) | Pharmaceutical compositions | |
Ahmad et al. | Recent advances in microencapsulation of drugs for veterinary applications | |
CN1895233A (zh) | 控释活性化合物的药物制剂 | |
EP1206247B1 (fr) | Composition pharmaceutique flottante comprenant une phase active et une phase non active | |
EP0437388B1 (fr) | Procédé d'incorporation dans des pellets de principes actifs protégés contre la dégradation dans la panse des ruminants | |
CN1882321A (zh) | 包含盐酸文拉法辛的小丸 | |
GB2539006A (en) | Functional feed | |
EP0588707B1 (fr) | Compositions nutritives ou médicamenteuses pour l'administration aux ruminants à base de chitosane | |
NO344096B1 (en) | Oral delivery system for bioactive active agents | |
CN1761453A (zh) | 口服控释药物递送系统 | |
CN1170523C (zh) | 用于植入的缓释药物制剂 | |
KR20080007202A (ko) | 키토산 비드를 이용한 비타민의 고정화 | |
CN112972411B (zh) | 一种盐酸二甲双胍缓释片组合物 | |
CN1138527C (zh) | 延时启动药剂的发送并完全释放药剂的渗透装置 | |
KR101812520B1 (ko) | 개선된 약제학적 스타터 펠렛 | |
US20210177761A1 (en) | Mucoadhesive polymer compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONMENT FOR FAILURE TO CORRECT DRAWINGS/OATH/NONPUB REQUEST |
|
AS | Assignment |
Owner name: EWOS INNOVATION AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JAYASINGHE, SUWAN NALIN;KLARIC, GORAN;WADSWORTH, SIMON;SIGNING DATES FROM 20150812 TO 20150908;REEL/FRAME:065575/0490 |